KeyWise

KeyWise AI operates at the intersection of digital health, cognitive monitoring, wellness software, and digital biomarkers. Its differentiation is the use of keyboard behavior—including typing speed, backspace activity, and autocorrect patterns—to produce continuous cognitive signals without analyzing the words a person types. Skye™ is positioned for several customer groups: individuals seeking brain-fitness feedback, clinicians monitoring patients remotely, digital therapeutics providers, payors, and pharmaceutical research teams. The Clarity Score™ and related warning triggers, treatment-response tracking, and Care Circles give the product a monitoring and support layer beyond a basic wellness assessment. It is therefore difficult to determine whether KeyWise competes primarily with cognitive-assessment platforms, remote patient-monitoring vendors, mental-health applications, or wellness trackers. The company’s strongest defensible positioning appears to be its privacy-preserving passive measurement model and research foundation, including claims of NIH-sponsored research and 10 peer-reviewed publications. These differentiators require continued clinical and commercial validation.

KeyWise AI was founded in 2019 by Raeanne Moore and appears to have progressed from research-led product development toward an early commercial model. The principal financing inflection point was its Apr 4, 2022 seed round, backed by Joyance Partners, Merus Capital, 3CC | Third Culture Capital, and TSVC. Product development has focused on Skye™, a custom smartphone keyboard and brain-fitness tracker that converts keystroke behavior into the Clarity Score™. The company also broadened its public visibility in December 2022 through an NIL agreement with Bella Rasmussen, suggesting an effort to connect cognitive performance and broader wellness branding with a high-profile athlete. Current staffing is recorded in the 1–10 employee range, with Raeanne Moore identified as a co-founder and current executive. Website activity signals cannot establish durable growth, and no later funding, hiring expansion, product launch, or acquisition is documented through Oct 2, 2026. The trajectory is consequently best characterized as early-stage and research-driven, with commercialization potential but limited verified scale indicators.